54 results about "Dna antibody" patented technology

This invention provides methods and devices for spatially separating at least first and second components in a sample which in one exemplary embodiment comprises introducing the first and second components into a first microfluidic channel of a microfluidic device in a carrier fluid comprising a spacer electrolyte solution and stacking the first and second components by isotachophoresis between a leading electrolyte solution and a trailing electrolyte solution, wherein the spacer electrolyte solution comprises ions which have an intermediate mobility in an electric field between the mobility of the ions present in the leading and trailing electrolyte solutions and wherein the spacer electrolyte solution comprises at least one of the following spacer ions MOPS, MES, Nonanoic acid, D-Glucuronic acid, Acetylsalicyclic acid, 4-Ethoxybenzoic acid, Glutaric acid, 3-Phenylpropionic acid, Phenoxyacetic acid, Cysteine, hippuric acid, p-hydroxyphenylacetic acid, isopropylmalonic acid, itaconic acid, citraconic acid, 3,5-dimethylbenzoic acid, 2,3-dimethylbenzoic acid, p-hydroxycinnamic acid, and 5-br-2,4-dihydroxybenzoic acid, and wherein the first component comprises a DNA-antibody conjugate and the second component comprises a complex of the DNA-antibody conjugate and an analyte.

This invention provides an antibody with high affinity for single-stranded DNA, low or no affinity for double-stranded DNA, and capable of specifically binding a DNA hairpin and the hybridoma cell lines which produces these monoclonal antibodies. A chimeric mouse comprising these hybridoma cell lines and a histocompatible mouse is further provided. A method for screening for an agent which will inhibit anti-DNA antibody.DNA binding. One such agent is a benzodiazepine derivative. This invention therefore provides a method of inhibiting the binding of an anti-DNA antibody to its DNA ligand in a sample by contacting the sample with an effective amount of a benzodiazepine derivative.

The present invention provides methods for isolating cell free nucleic acid, e.g., apoptotic or fetal nucleic acids and methods of detecting neoplastic cells or identifying the genetic composition of a fetus. The invention also provides magnetic particles comprising an anti-DNA antibody, and kits comprising the magnetic particles.

It is an object of the present invention to provide a solution for creating an effective method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis) without directly affecting the genetic apparatus of the ageing cells.

According to the invention this task is solved by administration into the blood circulation of the agent which inactivates extracellular blood plasma DNA; the extracellular blood DNA inactivating agent can be embodied in the form of an extracellular blood plasma DNA destroying agent; said extracellular blood plasma DNA destroying agent can be embodied in the form of an DNase enzyme; the extracellular blood plasma DNA inactivating agent can also be embodied in the form of an extracellular blood plasma DNA binding agent; the extracellular blood plasma DNA binding agent can be embodied in the form of anti-DNA antibodies; the extracellular blood plasma DNA inactivating agent can be administered in the form of an enzyme modifying the chemical composition of extracellular blood plasma DNA; the extracellular blood plasma DNA inactivating agent can be embodied in the form of an agent that stimulates synthesis or activity of endogenous deoxyribonuclease, or an agent that stimulates the synthesis of antibodies which capable to bind extracellular blood plasma DNA.

The invention relates to a nuclease amplified high-sensitivity electrochemical immunoassay method. The method comprises the steps of carrying out self-assembly to methylene blue (MB) marked hairpin DNA on the surface of a gold electrode to construct an electrochemical immunosensing interface under the Au-S bonding effect; enabling antibody 1, antibody 2 and antibody 3 to recognize target proteins simultaneously to form immune complex under the existence of the target proteins by taking the mixed solution of Mg<2+>, DNA1-antibody1, DNA2-antibody2 and DNA3-antibody3 as detection liquid, and enabling DNA1, DNA2 and DNA3 to be close with one another to perform ortho-position hybridization to form Mg<2+>-dependent nuclease, so as to perform catalytic cracking to the hairpin DNA on the sensing interface, so that the MB is separated from the surface of the electrode and the oxidized current is reduced; determining the concentration of the target protein by detecting the change of the current of the MB. The immunoassay method utilizes three DNA-antibody conjugates to form a nuclease amplified detection signal in an ortho-position manner, can improve the detection sensitivity and the selectivity, can detect the target proteins rapidly in a one-step manner, and has good clinical application value.

The invention discloses a magnetic particle-based quantitative chemiluminescent assay kit for an anti-double-stranded DNA antibody IgG. The kit comprises an anti-double-stranded DNA antibody IgG calibrator, an anti-double-stranded DNA antibody IgG quality control product, a Tris buffer containing biotin-labeled double-stranded DNA antigen and bovine serum albumin, a Tris buffer containing an alkaline phosphatase-labeled goat anti-human polyclonal antibody and bovine serum albumin, a Tris buffer containing streptavidin-labeled magnetic particles and bovine serum albumin, and a rinsing solution. The detection method using the kit improves sensitivity and a linearity range by 3 to 5 orders of magnitudes on the basis of a traditional membrane strip immunization method and a traditional enzyme linked immunosorbent assay method, realizes real quantitative determination, is rapid in reaction and reliable in results, can be automatically used in cooperation with an automatic chemiluminescence immunity analyzer and is of irreplaceable important value to clinical diagnosis.

The invention provides an adsorbent, a preparation method thereof, and an adsorption device for blood perfusion. The adsorbent is prepared by bonding phosphate group in DNA molecules to diazo acetic acid esterified polystyrene-divinyl benzene microspheres through covalent bonds. The preparation method comprises the following steps: preparing polystyrene-divinyl benzene microspheres, carrying out chloromethylation, carrying out alcoholization, and performing diazo acetic acid esterification to obtain the adsorbent. The adsorption device comprises the provided adsorbent. The adsorbent has a specific absorbing performance on anti-ds-DNA antibody. Through the covalent bond, the DNA can be more firmly loaded on the solid carriers, the efficiency is higher, and the DNA will not fall off from the carrier during the process of sterilization, storage, and using. The adsorbent can be applied to SLE and can also applied to autoimmune diseases such as myasthenia gravis, Guillain-Barre syndrome, rheumatoid arthritis, hypersensitive organ transplant patients, and the like.

The invention discloses an anti-double-stranded DNA antibodies IgG chemiluminescence immunoassay kit. The kit comprises biotinylated double-stranded DNA antigens, streptavidin-coated magnetic particles, acridine ester-labeled murine anti-human IgG monoclonal antibodies, anti-double-stranded DNA antibody IgG scaffolds, pre-excitation fluid and excitation fluid. Moreover a preparation method of the anti-double-stranded DNA antibodies IgG chemiluminescence immunoassay kit is also disclosed. Compared with the current kit the kit has the advantages of simple operation, high sensitivity and wide detection scope and the like.

The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing peptides recognized by monoclonal anti-DNA antibodies, the peptides having anti-apoptotic and anti-inflammatory activity. The invention further provides antibody molecules and uses thereof for the isolation of such peptides.

The invention relates to an SERS transverse flow test strip for nuclease detection and a detection method. The SERS transverse flow test strip comprises a bottom plate, a sample pad, a combination pad, a reaction film and a water absorption pad; the reaction film is provided with a detection line and a control line; the detection line is arranged at one end close to the combination pad, and the control line is arranged at one end close to the adsorption pad; the combination pad is coated with Raman reporter molecules and nanoparticles marked by detection DNA as SERS nanoprobes; streptavidin isfixed on the detection line; and an anti-single-chain DNA antibody is fixed on the control line. The SERS technology is used for quantitative analysis; the SERS signal is strong, no light drifts, thefingerprint information is rich, the stability is strong, the detection sensitivity is higher, the SERS transverse flow test strip is prepared by combining with an immunochromatography technology, the sample demand is low, the operation is simple and convenient, the reaction is fast, the result is accurate, the price is low, the detection limit is low, the selectivity is good, and the batch production is easy to realize.

The invention provides recombinant plasmid which is constructed by introducing 2 nucleotide sequences shown as SEQ ID NO:1 into a multiple cloning site area of pGEX-6P-1 plasmid. The invention further provides application of the recombinant plasmid and a detection kit for detecting double-stranded DNA antibody. The recombinant plasmid can serve as an antigen for detecting level of dsDNA antibody so as to screen risk of to-be-detected people populations in being affected with systemic lupus erythematosus; if expression level of the dsDNA antibody is high, the risk in being affected with systemic lupus erythematosus is high; if the expression level of the dsDNA antibody is low, the risk in being affected with systemic lupus erythematosus is low. The recombinant plasmid can be used for auxiliary diagnosis of clinical systemic lupus erythematosus and has good application prospect.

The invention relates to the technical field of biological medicine, in particular to application of an anti-double-stranded DNA antibody as a congenital megacolon diagnostic marker. The application comprises the following steps: screening a sample of a child patient with the congenital megacolon through a human autoimmune antigen chip to obtain an anti-double-stranded DNA (dsDNA) antibody with high plasma expression of the child patient with the congenital megacolon. The effectiveness of the anti-double-stranded DNA (dsDNA) antibody is verified in an independent sample by using an enzyme-linked immunosorbent assay (ELISA) method. The anti-double-stranded DNA (dsDNA) antibody can be used for effectively diagnosing children with congenital megacolon, and the AUC is 0.9167; the sensitivity corresponding to the optimal limit is 74.63%, and the specificity is 96.88%. The double-stranded DNA (dsDNA) antibody can be used as a congenital megacolon plasma diagnosis marker for screening and diagnosing diseases, and fills the blank of congenital megacolon plasma diagnosis.

The invention discloses a medical usage of russula griseocarnosa polysaccharide in treatment of systemic lupus erythematosus. The russula griseocarnosa polysaccharide PRG1-2 has the advantages of adjusting the activity of T cell subset, reducing IL-10, ds-DNA antibody and urine protein, being obviously effective in treatment, safe and reliable. Provided is an application of the russula griseocarnosa polysaccharide PRG1-2 with a wide clinical application prospect in preparation of medicine for treating systemic lupus erythematosus.

Compositions for improved gene editing and methods of use thereof are disclosed. In a preferred method, gene editing involves use of a cell-penetrating anti-DNA antibody, such as 3E10, as a potentiating agent to enhance gene editing by nucleases and triplex forming oligonucleotides. Genomic modification occurs at a higher frequency when cells are contacted with the potentiating agent and nuclease or triplex forming oligonucleotide, as compared to the absence of the potentiating agent. The methods are suitable for both ex vivo and in vivo approaches to gene editing and are useful for treating a subject with a genetic disease or disorder. Nanoparticle compositions for intracellular delivery of the gene editing compositions are provided and are particularly advantageous for use with in vivo applications.

The invention relates to the technical field of biological medicine, in particular to application of an anti-single-stranded DNA antibody as a congenital megacolon diagnostic marker. The application comprises the following steps: screening plasma of a child patient suffering from the congenital megacolon through a human autoimmune antigen chip to obtain an anti-single-stranded DNA (ssDNA) antibody highly expressed by the plasma of the child patient suffering from the congenital megacolon. The effectiveness of the anti-single-stranded DNA (ssDNA) antibody is verified in an independent sample by using an enzyme-linked immunosorbent assay (ELISA) method. The anti-single-stranded DNA (ssDNA) antibody can be used for effectively diagnosing children with congenital megacolon, and the AUC is 0.9167; the sensitivity corresponding to the optimal limit is 74.63%, and the specificity is 96.88%. The anti-single-stranded DNA (ssDNA) antibody can be used as a congenital megacolon plasma diagnosis marker for screening and diagnosing diseases, and fills the blank of congenital megacolon plasma diagnosis.

Disclosed herein are mono and bispecific DNA antibodies (DMAbs) targeting Pseudomonas aeruginosa. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering theDMAbs to the subject. The disclosure also provides a method of preventing and/or treating Pseudomonas aeruginosa infection in a subject using said composition and method of generation.

The invention discloses application of silicon dioxide nanoparticles to DNA (deoxyribonucleic acid) immunoadsorbent. The application has the advantages that the application is based on the merits which are discovered by the inventor and include the good adsorption performance and the excellent safety performance of the DNA immunoadsorbent, and DNA is loaded in silicon dioxide nanoparticles to obtain the DNA immunoadsorbent; the DNA immunoadsorbent with the DNA loaded in the silicon dioxide nanoparticles is obtained on the basis of the application, the DNA is modified in the surfaces or pore passages of the nanoparticles MSNs and SiO2 the immobilization amount is high, falling can be prevented, and accordingly the safety of the immunoadsorbent can be improved; DNA molecules and anti-ds-DNA(double-stranded DNA) antibodies can be in sufficient contact with one another, the specific binding capacity can be realized to the greatest extent, and accordingly the prepared immunoadsorbent is good and stable adsorption performance.

Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV -Envelope (anti-ZIKVE) Protein antibody.